178 related articles for article (PubMed ID: 32160077)
21. Population screening for smoldering multiple myeloma reveals high prevalence.
Nat Med; 2023 Feb; 29(2):313-314. PubMed ID: 36755165
[No Abstract] [Full Text] [Related]
22. Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140(8):828-838.
Blood; 2023 Mar; 141(11):1366. PubMed ID: 36929433
[No Abstract] [Full Text] [Related]
23. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
24. Is aggressive treatment of smoldering myeloma the path to curing myeloma?
Chakraborty R; Al Hadidi S; Cliff ERS; Mohyuddin GR
Blood Adv; 2023 Aug; 7(15):3932-3935. PubMed ID: 37196639
[No Abstract] [Full Text] [Related]
25. Identification of
Garcia JB; Storti P; Iannozzi NT; Marchica V; Agnelli L; Toscani D; Franceschi V; Todaro G; Sammarelli G; Notarfranchi L; Scita M; Palma BD; Raimondi V; Lungu O; Pruneri G; Donofrio G; Giuliani N
Haematologica; 2024 Feb; 109(2):627-631. PubMed ID: 37608776
[No Abstract] [Full Text] [Related]
26. Management of asymptomatic myeloma patients.
Mateos MV
Expert Rev Hematol; 2015 Feb; 8(1):19-27. PubMed ID: 25363073
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; López Corral L; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Olavarría E; Quintana N; García JL; Bladé J; Lahuerta JJ; San Miguel JF
N Engl J Med; 2013 Aug; 369(5):438-47. PubMed ID: 23902483
[TBL] [Abstract][Full Text] [Related]
28. The Role of Early Intervention in High-Risk Smoldering Myeloma.
Joseph NS; Dhodapkar MV; Lonial S
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141
[TBL] [Abstract][Full Text] [Related]
29. How We Approach Smoldering Multiple Myeloma.
Raje N; Yee AJ
J Clin Oncol; 2020 Apr; 38(11):1119-1125. PubMed ID: 32004107
[No Abstract] [Full Text] [Related]
30. [CME: Multiple Myeloma - a Review].
Bräutigam M; Biskup E
Praxis (Bern 1994); 2018 Jul; 107(14):749-754. PubMed ID: 29969971
[TBL] [Abstract][Full Text] [Related]
31. Smoldering multiple myeloma: present position and potential promises.
Tageja N; Manasanch EE; Korde N; Kwok M; Mailankody S; Bhutani M; Roschewski M; Landgren O
Eur J Haematol; 2014 Jan; 92(1):1-12. PubMed ID: 24112232
[TBL] [Abstract][Full Text] [Related]
32. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
Terpos E; Ntanasis-Stathopoulos I;
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
[TBL] [Abstract][Full Text] [Related]
33. Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon?
Chakraborty R
Eur J Cancer; 2022 Sep; 172():234-236. PubMed ID: 35797760
[No Abstract] [Full Text] [Related]
34. Physicians, paraproteins and progress: diagnosis and management of myeloma.
Pawlyn C; Jackson GH
Br J Hosp Med (Lond); 2019 Feb; 80(2):91-98. PubMed ID: 30746991
[TBL] [Abstract][Full Text] [Related]
35. Reversal of skin changes in smoldering myeloma with clinical presentation of POEMS syndrome with a lenalidomide-based regimen.
Solomou EE; Marnellos P; Agathokleous A; Kyriakou G; Georgiou S; Symeonidis A
Ann Hematol; 2019 Nov; 98(11):2625-2626. PubMed ID: 31650288
[No Abstract] [Full Text] [Related]
36. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
Maciocia N; Wechalekar A; Yong K
Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
[TBL] [Abstract][Full Text] [Related]
38. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
39. Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
Fawole A; Abonour R; Stender M; Shatavi S; Gaikazian S; Anderson J; Jaiyesimi I
Leuk Lymphoma; 2015 Jan; 56(1):34-41. PubMed ID: 24564573
[TBL] [Abstract][Full Text] [Related]
40. The difficult business of assessing new therapies for smouldering multiple myeloma.
Zonder JA
Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
